Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III randomized trial of induction chemotherapy with gemcitabine and carboplatin followed by elective paclitaxel consolidation versus paclitaxel and carboplatin followed by elective paclitaxel consolidation in patients with primary epithelial ovarian, primary peritoneal cancer or fallopian tube carcinoma.

Next Previous
X
Search
Trial Profile

Phase III randomized trial of induction chemotherapy with gemcitabine and carboplatin followed by elective paclitaxel consolidation versus paclitaxel and carboplatin followed by elective paclitaxel consolidation in patients with primary epithelial ovarian, primary peritoneal cancer or fallopian tube carcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2010 This trial will be featured in the Best of ASCO 2010.
    • 06 Jun 2010 Results were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 06 Jun 2010 Primary endpoint 'Progression free survival' has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top